Sugi Predict

Sugi Predict / Compounds / SCHEMBL11829

SCHEMBL11829

SCHEMBL11829

CC1(O)C(=O)Nc2cc(Br)ccc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.52
▸ KMT2A Q03164 2/20 0.52
▸ PIM1 P11309 2/20 0.49
▸ LMNA P02545 2/20 0.47
▸ L3MBTL1 Q9Y468 2/20 0.46
▸ GAA P10253 1/20 0.46
▸ PKM P14618 1/20 0.46
▸ PIM3 Q86V86 1/20 0.44
▸ PIM2 Q9P1W9 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.43
▸ CMA1 P23946 1/20 0.43
▸ AHR P35869 1/20 0.43
▸ POLB P06746 1/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ TP53 P04637 1/20 0.42
▸ CA1 P00915 1/20 0.38
▸ CA2 P00918 1/20 0.38
▸ CA4 P22748 1/20 0.38
▸ CA7 P43166 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31440532 1.00 MEN1 (0.52) MEN1KMT2APIM1LMNAL3MBTL1
SCHEMBL29502068 1.00 MEN1 (0.52) MEN1KMT2APIM1LMNAL3MBTL1
SCHEMBL3524533 0.86 LMNA (0.57) MEN1KMT2ALMNAL3MBTL1GAA
SCHEMBL29519108 0.81 PDK2 (0.55) MEN1KMT2APIM1LMNAL3MBTL1
SCHEMBL1223198 0.81 PDK2 (0.55) MEN1KMT2APIM1LMNAL3MBTL1
SCHEMBL23972238 0.80 AKR1B1 (0.45) KMT2ALMNAGAAALDH1A1POLB
SCHEMBL22128204 0.79 MEN1 (0.47) MEN1KMT2APIM1LMNAL3MBTL1
SCHEMBL25311315 0.79 CYP1A2 (0.41) KMT2APOLBCYP2C19CA1CA2
SCHEMBL25255334 0.79 MEN1 (0.46) MEN1KMT2APIM1LMNAL3MBTL1
SCHEMBL29337022 0.79 MEN1 (0.46) MEN1KMT2APIM1LMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12630516-B2 Compounds NRG THERAPEUTICS LTD. (GB) 2026-05-19 — — US disclosed
EP-4713096-A1 CDK INHIBITOR COMPOUNDS Aleksia Therapeutics, Inc. (US) 2026-03-25 — — EP disclosed
US-20260028348-A1 MODULATORS OF TNF-ALPHA ACTIVITY FORWARD THERAPEUTICS INC (US) 2026-01-29 — — US disclosed
EP-4371987-B9 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS GILEAD SCIENCES INC (US) 2025-11-26 — — EP disclosed
EP-4208442-B1 MPTP INHIBITORS NRG THERAPEUTICS LTD (GB) 2025-10-22 — — EP disclosed
EP-4371987-B1 SUBSTITUTED 6-AZABENZIMIDAZOLE COMPOUNDS AS HPK1 INHIBITORS GILEAD SCIENCES INC (US) 2025-09-17 — — EP disclosed
US-20250179028-A1 ACRYLAMIDE COMPOUNDS NRG THERAPEUTICS LTD (GB) 2025-06-05 — — US disclosed
US-12258346-B2 Substituted 6-azabenzimidazole compounds GILEAD SCIENCES, INC. (US) 2025-03-25 — — US disclosed
EP-4486721-A1 ACRYLAMIDE COMPOUNDS NRG Therapeutics LTD (GB) 2025-01-08 — — EP disclosed
WO-2024238574-A1 CDK INHIBITOR COMPOUNDS ALEKSIA THERAPEUTICS, INC. (US) 2024-11-21 — — WO disclosed
US-8394969-B2 Cyclic benzimidazole derivatives useful as anti-diabetic agents MERCK SHARP & DOHME CORP. (US) 2013-03-12 — — US disclosed
US-8329914-B2 Cyclic benzimidazole derivatives useful as anti-diabetic agents MERCK SHARP & DOHME CORP (US) 2012-12-11 — — US disclosed
EP-2496567-A2 NOVEL BENZOPYRAN KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2012-09-12 — — EP disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 — — US disclosed
US-20110263533-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS MERCK SHARP & DOHME CORP. 2011-10-27 — — US disclosed
US-20110218174-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS MERCK SHARP & DOHME CORP. (US) 2011-09-08 — — US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 — — US disclosed
WO-2011055215-A2 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2011-05-12 — — WO disclosed
US-20100081643-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS MERCK SHARP & DOHME LLC 2010-04-01 — — US disclosed
WO-2010036613-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL ANTI-DIABETIC AGENTS MERCK SHARP & DOHME CORP. (US) 2010-04-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12258346-B2 Substituted 6-azabenzimidazole compounds CDK6, HIPK1, DCK MEN1 2632/4885KMT2A 1111/4885PIM1 886/4885
US-12630516-B2 Compounds CYP4B1, CYP1B1, NR4A1 MEN1 1126/4885KMT2A 761/4885PIM1 3622/4885
US-20110263533-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS PRKAG2, PRKAG1, PRKAB2 MEN1 3565/4885KMT2A 2171/4885PIM1 847/4885
US-20100081643-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS PRKAG2, PRKAG1, PRKAB2 MEN1 3565/4885KMT2A 2171/4885PIM1 847/4885
US-20250179028-A1 ACRYLAMIDE COMPOUNDS ACR, CCNI, FANCI MEN1 699/4885KMT2A 3787/4885PIM1 1924/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB MEN1 4673/4885KMT2A 3137/4885PIM1 735/4885
US-20110218174-A1 NOVEL CYCLIC BENZIMIDAZOLE DERIVATIVES USEFUL AS ANTI-DIABETIC AGENTS PRKAG2, PRKAG1, PRKAB2 MEN1 3565/4885KMT2A 2171/4885PIM1 847/4885
US-20260028348-A1 MODULATORS OF TNF-ALPHA ACTIVITY TNF, TNFRSF1A, TNFRSF9 MEN1 2098/4885KMT2A 4607/4885PIM1 4141/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB MEN1 4673/4885KMT2A 3137/4885PIM1 735/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.